No Data
No Data
No Data
No Data
No Data
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1
Shanghai Henlius Biotech (HKG:2696) recorded an operating income of about 1.35 billion yuan for the first quarter of the year, according to the company's filing on the Hong Kong Stock Exchange. Two of
MT NewswiresMay 1 16:36
Henlius Trastuzumab Receives FDA Approval in the United States
Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas...
PR NewswireApr 29 20:26
Fuhong Hanlin (02696) achieved revenue of about 1,349 billion yuan in the first quarter
Zhitong Finance App News, Fu Hong Han Lin (02696) announced that in the first quarter of 2024, the Group will seize its existing first-mover advantage, comprehensively promote the product commercialization process, and continue to build innovative business models and optimize resource allocation. During the reporting period, the Group achieved revenue of approximately RMB 1,349 billion. The results of the two core products sold and promoted in China (excluding Hong Kong, Macao and Taiwan regions, same below) led by the Group's self-built commercial team during the reporting period are as follows: Han Quyou (trastuzumab for injection, European trade name: Zercepac, US product name: HERCESSITM,
Zhitong FinanceApr 29 16:34
Shanghai Henlius Biotech's Cancer Drug Gets the Nod From US FDA
The US Food and Drug Administration (FDA) approved Shanghai Henlius Biotech's (HKG:2696) drug HLX02 (trastuzumab for injection) for the treatment of multiple cancers, according to a Friday Hong Kong b
MT NewswiresApr 26 14:54
Express News | Fuhong Hanlin HLX02 was approved by the FDA.
BreakingsApr 26 12:22
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech (HKG:2696) has dosed the first subject in a phase I clinical study of HLX6018 in healthy subjects in mainland China, a Tuesday filing on the Hong Kong bourse stated. HLX6018 i
MT NewswiresApr 24 17:28
No Data
No Data